KRAS mutations are among the most common genetic alterations in cancer and are considered particularly difficult to treat. In ...

"The benefit of this 'multi-selective' approach is that the inhibitors are designed to inhibit multiple RAS mutations, so if ...

Hecht, MD, discusses the phase 3 OrigAMI-3 trial for patients with recurrent, unresectable, or metastatic RAS/BRAF wild-type colorectal cancer.

"The gene can have a mutation, which I happen to have ... that signals the body to behave in a way that can halt cancer growth. "K-RAS is a gene that is an on-switch in many of these cancers ...

Two studies presented at ASCO's annual meeting used ctDNA testing to determine which patient might benefit from anti-EGFR retreatment.

About Non-Small Cell Lung Cancer and RAS Mutations More than 197,000 people are diagnosed with non-small cell lung cancer (NSCLC) in the U.S. each year.1 Despite treatment advancements ...

Researchers are trying to better understand how co-mutations and PD-L1 expression impact response to single-agent KRAS G12C ...

Explore how cutting-edge agents like alpelisib, capivasertib, MEK and ERK inhibitors, and JAK inhibitors are reshaping the ...